Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 6/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | IGF2R | P11717 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17993275 | 0.96 | SIRT5 (0.44) | SIRT5SIRT6SIRT1SIRT2ALB | |
| SCHEMBL25092038 | 0.96 | SIRT5 (0.44) | SIRT5SIRT6SIRT1SIRT2ALB | |
| SCHEMBL17841852 | 0.90 | SIRT5 (0.49) | SIRT5SIRT6SIRT1SIRT2ALB | |
| SCHEMBL19776854 | 0.90 | SIRT5 (0.49) | SIRT5SIRT6SIRT1SIRT2ALB | |
| SCHEMBL19171358 | 0.86 | SIRT5 (0.40) | SIRT5SIRT6SIRT1SIRT2FURIN | |
| SCHEMBL18688864 | 0.86 | GNPAT (0.45) | SIRT5SIRT6SIRT1ALBFURIN | |
| SCHEMBL28574926 | 0.86 | GNPAT (0.45) | SIRT5SIRT6SIRT1ALBFURIN | |
| SCHEMBL18122890 | 0.85 | SIRT5 (0.37) | SIRT5SIRT6SIRT1SIRT2FURIN | |
| SCHEMBL29296435 | 0.85 | SIRT5 (0.41) | SIRT5SIRT6SIRT1SIRT2FURIN | |
| SCHEMBL18661755 | 0.85 | SIRT5 (0.36) | SIRT5SIRT6SIRT1FURINKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885SIRT6 3131/4885SIRT1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.